Immunic Inc (NASDAQ:IMUX) chief scientific officer Dr Hella Kohlhof talked with Proactive about the company’s research focus on multiple sclerosis (MS), highlighting how Immunic is aiming to address both the physical and mental health challenges faced by patients. Kohlhof explained the strong link between MS and mental health conditions such as depression and anxiety, noting that studies show around 30% of patients experience depression, while 20% experience anxiety. “These challenges are often invisible to the world outside, but have a huge impact on daily life and overall well-being,” she said. Discussing Immunic’s work, Kohlhof emphasised the company’s focus on slowing disease progression, including Progression Independent of Relapse Activity (PIRA), which accounts for over 50% of disability accumulation in MS patients. Positive long-term data were seen in Immunic’s Phase 2 EMPhASIS trial for relapsing-remitting MS, with a low incidence of PIRA over multiple years. She also highlighted recent positive Phase 2 CALLIPER data in progressive MS, a form of the disease with few available treatments. The goal, she said, is to “give these patients...hope for a future where effective treatment is available.” Kohlhof called for the integration of mental health into all stages of MS care and expressed a personal commitment to improving patients’ quality of life. For more expert insights, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications for future updates. #ImmunicInc #MultipleSclerosis #MSResearch #MentalHealth #MSAwareness #VidofludimusCalcium #PIRA #EMPhASISTrial #CALLIPERTrial #Neurology #ProactiveInvestors